整合素连接激酶在前列腺癌组织中的表达及意义

目的: 探讨整合素连接激酶(ILK)在前列腺癌组织中的表达及其临床意义。　方法: 应用免疫组化SP法测定 50例前列腺癌及 16例良性前列腺增生组织中ILK的表达。　结果: 前列腺癌组织中ILK阳性表达率46. 0%(23 /50),肿瘤病理分级:高分化组阳性表达率为9. 0% ( 1 /11 ),中分化组为35. 7% ( 5 /14 ),低分化组68. 0% ( 17 /25),随肿瘤病理分级高分化组到低分化组,阳性表达率有趋势性增高。临床分期A+B期为22. 5% (7 /31)和C+D期为84. 2% (16 /19),临床分期程度的增高,癌细胞ILK阳性表达率明显增加。良性前列腺增生组织ILK阳性表达率仅为6. 2% (1 /16),明显低于前列腺癌组织(χ2 =8. 27,P<0. 01)。　结论: ILK异常表达在前列腺癌的恶性进展中起重要作用,检测ILK的表达有帮助于判断病期及预后。

Expression of Integrin-linked Kinase in Prostate Cancer and Its Significance

OBJECTIVE: To investigate the expression of integrin-linked kinase (ILK) in primary prostate cancer and its clinical significance. METHODS: The expression of ILK was analysed in 50 prostate cancer and 16 benign prostatic hyperplasia samples by immunohistochemical staining. RESULTS: The positive percentage of ILK was 46.0% (23/50) in primary prostate cancer. The higher the grade and the clinical stage of the tumor, the lower the expression of ILK. The positive percentages of ILK were 9.1% (1/11) in the well differentiated type, 56.4% (22/39) in the moderately and poorly differentiated type (chi2 = 12.28, P < 0.01), 24.0% (6/25) in the well and moderately differentiated type, 68.0% (17/25) in the poorly differentiated type (chi2 = 9.74, P < 0.01), 22.6% (7/31) at the A + B stage and 84.0% (16/19) at the C + D stage (chi2 = 11.8, P < 0.01). But in benign prostatic hyperplasia, it was only 6.2% (1/16), significantly lower than in primary prostate cancer (46.0%) (chi2 = 8.27, P < 0.01). CONCLUSION: The abnormal expression of ILK plays an important role in the development of primary prostate cancer, and the detection of ILK may be useful for the judgement of tumor development and prognosis.